EYEPOINT INC (EYPT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EYPT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EYPT | Director | 80 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BBIO | Director and Lead Independent Director | 80 | [] | [] | 2026 |
| PGEN | Director | 80 | ["Chairman and Chief Executive Officer of Schering-Plough","Chairman and Chief Executive Officer of Pharmacia Corporation","Leadership positions with Wyeth","Previous directorships at Time Warner Inc. and Amgen, Inc."] | ["Compensation and Human Capital Management","Audit"] | 2026 |
| AMGN | [] | [] | 2022 |
Biography sourced from the proxy statement filing.
Mr. Hassan joined Warburg Pincus LLC, a global private equity institution, in 2010 and currently serves as Director. Previously, Mr. Hassan served as Chairman and Chief Executive Officer of Schering-Plough from 2003 to 2009. Before assuming these roles, from 2001 to 2003, Mr. Hassan was Chairman and Chief Executive Officer of Pharmacia Corporation, a company formed as a result of the merger of Monsanto Company and Pharmacia & Upjohn, Inc. He joined Pharmacia & Upjohn, Inc. as Chief Executive Officer in 1997. Mr. Hassan previously held leadership positions with Wyeth serving as Executive Vice President and was a member of the board from 1995 to 1997. Earlier in his career, he spent a significant tenure with Sandoz Pharmaceuticals (now Novartis) and headed the company s U.S. pharmaceuticals business. Mr. Hassan has served as a director of Precigen Inc. (NASDAQ: PGEN) since June 2016, a director of BridgeBio Pharma Inc. (NASDAQ: BBIO) since August 2021, and a director of Cocrystal (NASDAQ: COCP) since July 2023. Mr. Hassan previously served as a director of Prometheus Biosciences Inc. from May 2021 to June 2023, a director of Amgen, Inc. (NASDAQ: AMGN) from July 2015 to May 2021, and as a director of Time Warner Inc. from October 2009 to June 2018. In the course of his career, he has held numerous directorships, including those at Avon Products, Inc. from 1999 to 2013, Bausch & Lomb from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc. in 2013, and Valeant Pharmaceuticals International, Inc. from 2013 to 2014. Mr. Hassan has chaired notable pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School. We believe Mr. Hassan is qualified to serve on the Board because of his extensive leadership and Board experience, having guided numerous life science companies as CEO, Chairman and Director.